

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3202991


SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BAYER PHARMA AKTIENGESELLSCHAFT	01/29/2015
RECEIVING PARTY DATA	
Name:	BAYER INTELLECTUAL PROPERTY GMBH
Street Address:	ALFRED-NOBEL-STRASSE 10
City:	MONHEIM
State/Country:	GERMANY
Postal Code:	40789
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	6432948
Patent Number:	6133260
CORRESPONDENCE DATA	
Fax Number:	(212)808-0844
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212-808-0700
Email:	mferguson@nmmlaw.com
Correspondent Name:	GERSTENZANG, WILLIAM C.
Address Line 1:	NORRIS MCLAUGHLIN & MARCUS P.A.
Address Line 2:	875 THIRD AVE, 8TH FLOOR
Address Line 4:	NEW YORK, NEW YORK 10022
ATTORNEY DOCKET NUMBER:	100717-209 WCG
NAME OF SUBMITTER:	WILLIAM C. GERSTENZANG
SIGNATURE:	/William C. Gerstenzang/
DATE SIGNED:	01/29/2015
Total Attachments: 1	
source=Bayer_Pharma_to_BIP#page1.tif	


ASSIGNMENT OF INVENTION


In consideration of the representations, warranties, covenants, and agreements in the Einbringungsvertrag ("Contribution Agreement") dated as of March 30, 2012 and effective as of April 1, 2012, by and among Bayer Pharma Aktiengesellschaft, a corporation registered with the local court of Charlottenburg, Germany, with an office at Mullerstrasse 178, 13353 Berlin, GERMANY (ASSIGNOR), and Bayer Intellectual Property GmbH, with an office at Alfred-Nobel-Strasse 10, 40789 Monheim am Rhein, GERMANY (ASSIGNEE), and confirmatory to the assignments of U.S. patents and applications contained in that Contribution Agreement,


ASSIGNOR hereby confirms the assignment and transfer (effective on April 1, 2012) to ASSIGNEE of the ASSIGNOR's entire right, title and interest in and to, including the right to claim priority from, the invention(s) disclosed in the granted patents U.S. Patent Nos. 6,432,948 and 6,133,260, and in and to all Letters Patent and equivalents thereof to be obtained for said invention in the United States by the above patents or any continuation, division, renewal, substitute or equivalent thereof, as well as to any reissue, reexamination, patent term restoration, or equivalent thereto.

IN WITNESS WHEREOF, I/we have hereunto respectively set hand(s) and seal(s) on the date(s) shown below:



on behalf of
Bayer Pharma Aktiengesellschaft
Dr. Alexander Nowak
Assistant Chief Patent Counsel


Dr. Markus Allers
Senior Patent Counsel



on behalf of
Bayer Intellectual Property GmbH
Dr. Frank Burkert
Senior Patent Counsel


Dr. Jörg Thomae
Managing Director

Typed Name and Title of Official
signing on behalf of
Bayer Pharma Aktiengesellschaft


Date

Typed Name and Title of Official
signing on behalf of
Bayer Intellectual Property GmbH


Date